Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
$37.87
+2.0%
$38.54
$26.20
$63.50
$1.75B1.42419,769 shs498,293 shs
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
$6.99
+1.2%
$7.70
$6.61
$18.62
$412.93M-0.08419,350 shs741,007 shs
Mesoblast Limited stock logo
MESO
Mesoblast
$14.39
+6.4%
$14.08
$6.00
$22.00
$1.84B2.26180,119 shs379,111 shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$18.71
+1.4%
$17.78
$10.41
$138.81
$1.83B0.498.85 million shs5.17 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
+1.99%+4.12%+3.49%-7.59%-19.34%
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
+1.16%-7.29%-11.29%-23.02%-62.58%
Mesoblast Limited stock logo
MESO
Mesoblast
+6.43%+4.05%-8.11%+22.05%+119.69%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
+1.35%+2.80%+15.07%-56.50%-86.12%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
$37.87
+2.0%
$38.54
$26.20
$63.50
$1.75B1.42419,769 shs498,293 shs
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
$6.99
+1.2%
$7.70
$6.61
$18.62
$412.93M-0.08419,350 shs741,007 shs
Mesoblast Limited stock logo
MESO
Mesoblast
$14.39
+6.4%
$14.08
$6.00
$22.00
$1.84B2.26180,119 shs379,111 shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$18.71
+1.4%
$17.78
$10.41
$138.81
$1.83B0.498.85 million shs5.17 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
+1.99%+4.12%+3.49%-7.59%-19.34%
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
+1.16%-7.29%-11.29%-23.02%-62.58%
Mesoblast Limited stock logo
MESO
Mesoblast
+6.43%+4.05%-8.11%+22.05%+119.69%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
+1.35%+2.80%+15.07%-56.50%-86.12%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
2.88
Moderate Buy$97.29156.89% Upside
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
3.00
Buy$26.80283.40% Upside
Mesoblast Limited stock logo
MESO
Mesoblast
3.20
Buy$18.0025.09% Upside
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
2.07
Hold$43.50132.50% Upside

Current Analyst Ratings Breakdown

Latest CGEM, SRPT, MESO, and APGE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/28/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/28/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$78.00 ➝ $87.00
8/25/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell
8/21/2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$24.00
8/20/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetUnderperform$17.00
8/18/2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$35.00 ➝ $28.00
8/15/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetSell$12.00
8/14/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
8/11/2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$90.00
8/7/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$19.00
8/7/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$48.00 ➝ $50.00
(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
N/AN/AN/AN/A$15.92 per shareN/A
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/AN/AN/AN/A$10.14 per shareN/A
Mesoblast Limited stock logo
MESO
Mesoblast
$17.20M107.09N/AN/A$4.21 per share3.42
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$1.90B0.96$2.44 per share7.68$15.99 per share1.17
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
-$182.15M-$4.13N/AN/AN/AN/A-34.65%-32.76%11/11/2025 (Estimated)
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$167.38M-$3.23N/AN/AN/AN/A-36.56%-34.82%11/6/2025 (Estimated)
Mesoblast Limited stock logo
MESO
Mesoblast
-$87.96MN/A0.00N/AN/AN/AN/AN/AN/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$235.24M-$0.87N/A1.71N/A-2.34%-1.03%-0.37%11/5/2025 (Estimated)

Latest CGEM, SRPT, MESO, and APGE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
-$1.03-$1.13-$0.10-$1.13N/AN/A
8/7/2025Q2 2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$0.83-$1.07-$0.24-$1.07N/AN/A
8/6/2025Q2 2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$0.89$2.02+$1.13$1.89$530.66 million$611.09 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
N/AN/AN/AN/AN/A
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/AN/AN/AN/AN/A
Mesoblast Limited stock logo
MESO
Mesoblast
N/AN/AN/AN/AN/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
N/A
16.36
16.36
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/A
9.83
9.83
Mesoblast Limited stock logo
MESO
Mesoblast
0.11
1.99
0.63
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
0.84
2.89
1.81

Institutional Ownership

CompanyInstitutional Ownership
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
79.04%
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
86.31%
Mesoblast Limited stock logo
MESO
Mesoblast
1.43%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
86.68%

Insider Ownership

CompanyInsider Ownership
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
42.77%
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
7.16%
Mesoblast Limited stock logo
MESO
Mesoblast
18.80%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apogee Therapeutics Inc. stock logo
APGE
Apogee Therapeutics
9146.11 million26.39 millionOptionable
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
3059.07 million54.84 millionOptionable
Mesoblast Limited stock logo
MESO
Mesoblast
80128.00 million103.93 millionOptionable
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
1,37297.71 million90.29 millionOptionable

Recent News About These Companies

Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 6.1% - Still a Buy?
Sarepta Therapeutics (SRPT) Fell Despite Reporting Good Results
Sarepta Therapeutics, Inc. $SRPT Shares Sold by Braidwell LP

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Apogee Therapeutics stock logo

Apogee Therapeutics NASDAQ:APGE

$37.87 +0.74 (+1.99%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$37.33 -0.54 (-1.42%)
As of 09/5/2025 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Cullinan Therapeutics stock logo

Cullinan Therapeutics NASDAQ:CGEM

$6.99 +0.08 (+1.16%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$7.13 +0.14 (+2.02%)
As of 09/5/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Mesoblast stock logo

Mesoblast NASDAQ:MESO

$14.39 +0.87 (+6.43%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$14.07 -0.32 (-2.22%)
As of 09/5/2025 07:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Sarepta Therapeutics stock logo

Sarepta Therapeutics NASDAQ:SRPT

$18.71 +0.25 (+1.35%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$18.63 -0.08 (-0.41%)
As of 09/5/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.